Axsome Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $150,042 | $121,463 | $118,766 | $104,762 |
Gross Profit | 136,594 | 111,674 | 108,252 | 96,325 |
EBITDA | -36,714 | -56,982 | -70,544 | -60,563 |
EBIT | -61,844 | -72,617 | -62,624 | |
Net Income | -47,973 | -59,413 | -74,912 | -64,602 |
Net Change In Cash | 150,042 | 121,463 | 118,766 | 104,762 |
Free Cash Flow | -32,423 | -43,375 | -26,232 | -18,481 |
Cash | 303,016 | 300,910 | 315,353 | 327,341 |
Basic Shares | 49,442 | 48,871 | 48,542 | 48,141 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $385,693 | $270,600 | $50,037 | $8,819 |
Gross Profit | 352,390 | 244,535 | 44,839 | -1,155 |
EBITDA | -272,604 | -224,991 | -174,234 | -123,551 |
EBIT | -280,562 | -231,825 | -179,799 | -124,706 |
Net Income | -287,216 | -239,238 | -197,766 | -134,943 |
Net Change In Cash | 385,693 | 270,600 | 50,037 | 8,819 |
Cost of Revenue | -97,403 | |||
Free Cash Flow | -128,680 | -145,662 | -117,212 | -108,533 |
Cash | 315,353 | 386,193 | 200,841 | 86,472 |
Basic Shares | 47,914 | 45,425 | 40,655 | 37,618 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.97 |
2025-03-31 | -$1.21 |
2024-12-31 | -$1.54 |
